Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis

BACKGROUND: Surrogate endpoints (SEs), such as progression-free survival (PFS) and objective response rate (ORR), are frequently used in clinical trials. The relationship between SEs and overall survival (OS) has not been well described in metastatic urothelial cancer (MUC). OBJECTIVE: We evaluated...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron: Ghali, Fady, Zhao, Yibai, Patel, Devin, Jewell, Teresa, Yu, Evan Y., Grivas, Petros, Montgomery, R. Bruce, Gore, John L., Etzioni, Ruth B., Wright, Jonathan L.
Fformat: Online Erthygl Texto
Iaith:English
Cyhoeddwyd: Elsevier 2022
Pynciau:
Bladder Cancer
Mynediad Ar-lein:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806712/
https://www.ncbi.nlm.nih.gov/pubmed/36601043
http://dx.doi.org/10.1016/j.euros.2022.11.003

Rhyngrwyd

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806712/
https://www.ncbi.nlm.nih.gov/pubmed/36601043
http://dx.doi.org/10.1016/j.euros.2022.11.003

Eitemau Tebyg